The SMART Prices Act is anything but smart | The Hill | 06/29/23

By Thomas Philipson America’s largest pharmaceutical companies continue to sound the alarm about last year’s Inflation Reduction Act. In late May, Novartis announced that it had already dropped some early-stage cancer drugs because of Medicare’s new power to dictate...
Scroll to Top